XTNT - Xtant Medical Holdings Inc Stock Price, Fair Value and News

0.73USD+0.04 (+5.80%)Market Closed

Market Summary

USD0.73+0.04

Market Closed

5.80%

XTNT Stock Price

View Fullscreen

XTNT RSI Chart

XTNT Valuation

Market Cap

95.1M

Price/Earnings (Trailing)

-57.19

Price/Sales (Trailing)

0.94

EV/EBITDA

29.8

Price/Free Cashflow

-6.4

XTNT Price/Sales (Trailing)

XTNT Profitability

EBT Margin

-3.26%

Return on Equity

-3.49%

Return on Assets

-1.77%

Free Cashflow Yield

-15.61%

XTNT Fundamentals

XTNT Revenue

Revenue (TTM)

101.2M

Rev. Growth (Yr)

55.34%

Rev. Growth (Qtr)

-0.84%

XTNT Earnings

Earnings (TTM)

-1.7M

Earnings Growth (Yr)

-111.74%

Earnings Growth (Qtr)

-2.25%

Breaking Down XTNT Revenue

Last 7 days

-9.9%

Last 30 days

-6.4%

Last 90 days

-31.1%

Trailing 12 Months

21.5%

How does XTNT drawdown profile look like?

XTNT Financial Health

Current Ratio

2.34

Debt/Equity

0.35

Debt/Cashflow

-0.78

XTNT Investor Care

Shares Dilution (1Y)

19.58%

Diluted EPS (TTM)

-0.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	101.2M	0	0	0
2023	63.0M	67.9M	78.5M	91.3M
2022	55.7M	56.0M	56.7M	58.0M
2021	51.1M	55.5M	55.3M	55.3M
2020	62.7M	58.0M	56.3M	53.3M
2019	71.0M	67.5M	66.0M	64.7M
2018	78.5M	75.8M	73.3M	72.2M
2017	91.1M	91.1M	87.8M	82.6M
2016	70.8M	82.4M	87.8M	90.0M
2015	35.9M	36.9M	46.2M	59.3M
2014	33.4M	34.0M	34.5M	35.3M
2013	33.8M	33.9M	32.9M	33.1M
2012	31.9M	32.6M	34.0M	33.0M
2011	19.1M	22.8M	26.5M	30.1M
2010	0	0	0	15.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Xtant Medical Holdings Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 03, 2024	brandt kevin d	acquired	-	-	184,209	chief commercial officer
Apr 03, 2024	neils scott c	acquired	-	-	177,551	chief financial officer
Apr 03, 2024	schallenberger mark a.	acquired	-	-	177,551	chief operations officer
Apr 03, 2024	browne sean e	acquired	-	-	731,632	president and ceo
Jan 16, 2024	neils scott c	sold (taxes)	-8,704	1.09	-7,986	chief financial officer
Nov 17, 2023	brandt kevin d	bought	49,837	1.196	41,670	chief commercial officer
Oct 15, 2023	browne sean e	sold (taxes)	-113,877	1.08	-105,442	president and ceo
Oct 15, 2023	browne sean e	sold (taxes)	-120,659	1.08	-111,721	president and ceo
Aug 15, 2023	bakewell john k	acquired	-	-	145,180	-
Aug 15, 2023	neils scott c	acquired	-	-	116,144	chief financial officer

Which funds bought or sold XTNT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	AWM Investment Company, Inc.	reduced	-19.3	-87,107	442,501	0.06%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	49.74	99,102	279,168	-%
May 15, 2024	CITADEL ADVISORS LLC	added	9.33	8,931	76,580	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	sold off	-100	-37,489	-	-%
May 15, 2024	Royal Bank of Canada	new	-	1,000	1,000	-%
May 15, 2024	ORBIMED ADVISORS LLC	unchanged	-	2,924,580	85,544,100	1.57%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	14,740	431,145	0.01%
May 15, 2024	Nantahala Capital Management, LLC	reduced	-50.00	-4,360,000	4,680,000	0.27%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-78.14	-9,046	2,647	-%
May 15, 2024	Altium Capital Management LP	reduced	-4.73	-123,169	8,948,010	3.54%

Are Funds Buying or Selling XTNT?

Are funds buying XTNT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own XTNT

No. of Funds

Unveiling Xtant Medical Holdings Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	altium capital management lp	6.2%	8,027,593	SC 13G/A
Aug 03, 2023	orbimed advisors llc	56.7%	73,114,592	SC 13D/A
May 05, 2023	orbimed advisors llc	67.1%	73,114,592	SC 13D/A
Feb 14, 2023	altium capital management lp	5.7%	6,246,291	SC 13G/A
Sep 06, 2022	vizirgianakis stavros g.	6.62%	7,224,924	SC 13D
Aug 30, 2022	orbimed advisors llc	67.9%	73,114,592	SC 13D/A
Feb 14, 2022	altium capital management lp	7.2%	6,246,291	SC 13G/A
Apr 09, 2021	orbimed advisors llc	84.0%	72,873,494	SC 13D/A
Mar 08, 2021	altium capital management lp	9.99%	8,663,889	SC 13G
Feb 26, 2021	orbimed advisors llc	93.6%	72,803,072	SC 13D/A

Recent SEC filings of Xtant Medical Holdings Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	8-K	Current Report
May 15, 2024	10-Q	Quarterly Report
Apr 08, 2024	EFFECT	EFFECT
Apr 05, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Apr 04, 2024	CORRESP	CORRESP
Apr 02, 2024	UPLOAD	UPLOAD
Apr 01, 2024	S-3	S-3

Peers (Alternatives to Xtant Medical Holdings Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

Xtant Medical Holdings Inc News

Latest updates

Xtant Medical Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-0.8%	27,873,000	28,108,500	25,019,000	20,232,000	17,943,000	15,270,500	14,462,000	15,277,000	12,959,000	13,969,500	13,777,000	14,975,000	12,542,000	14,014,500	14,016,000	10,529,000	14,778,000	16,964,000	15,721,000	15,271,000	16,726,000
Gross Profit	1.0%	17,302,000	17,137,500	15,334,000	12,459,000	10,536,000	8,306,500	7,896,000	8,374,000	7,560,000	7,694,000	7,191,000	9,515,000	8,091,000	8,982,000	9,248,000	6,550,000	9,613,000	11,398,500	10,411,000	9,906,000	10,813,000
Operating Expenses	-0.8%	20,772,000	20,943,500	18,719,000	13,850,000	12,112,000	10,030,500	9,796,000	9,674,000	9,391,000	9,606,000	8,636,000	10,006,000	8,096,000	8,742,500	8,488,000	6,937,000	10,976,000	11,716,000	11,116,000	10,469,000	11,481,000
S&GA Expenses	7.6%	12,460,000	11,584,000	11,085,000	8,716,000	7,054,000	5,832,000	5,838,000	5,636,000	5,209,000	5,313,000	5,267,000	5,590,000	4,855,000	5,405,000	5,270,000	3,895,000	6,413,000	6,994,000	6,685,000	6,072,000	6,742,000
R&D Expenses	7.1%	527,000	492,000	490,000	180,000	174,000	232,000	229,000	241,000	213,000	151,000	262,000	243,000	214,000	126,500	176,000	111,000	245,000	257,000	203,000	210,000	262,000
EBITDA Margin	-36.0%	0.04	0.06	0.07	-0.07	-0.08	-0.09	-0.10	-0.09	-0.08	-0.05	0.00	0.04	-	-	-	-	-	-	-	-	-
Interest Expenses	2.1%	835,000	817,500	760,000	786,000	575,000	495,500	440,000	397,000	359,000	466,000	329,000	199,000	1,000	717,500	2,097,000	2,054,000	1,108,000	1,268,000	1,185,000	1,301,000	2,018,000
Income Taxes	-88.2%	68,000	577,000	-2,300,000	13,000	13,000	20,500	13,000	13,000	23,000	-	30,000	43,000	23,000	228,000	23,000	23,000	22,000	30,000	23,000	22,000	23,000
Earnings Before Taxes	-16.3%	-4,332,000	-3,726,000	6,931,000	-2,177,000	-2,065,000	-2,188,500	-2,340,000	-1,697,000	-2,190,000	-2,378,000	-1,774,000	-690,000	-6,000	-478,000	-1,337,000	-2,441,000	-2,471,000	-1,574,500	-1,856,000	-1,917,000	-2,776,000
EBT Margin	-187.4%	-0.03	-0.01	0.01	-0.13	-0.13	-0.15	-0.15	-0.14	-0.13	-0.09	-0.05	-0.05	-	-	-	-	-	-	-	-	-
Net Income	-2.3%	-4,400,000	-4,303,000	9,231,000	-2,190,000	-2,078,000	-2,209,000	-2,353,000	-1,710,000	-2,213,000	-2,283,000	-1,804,000	-733,000	-29,000	-706,000	-1,360,000	-2,464,000	-2,493,000	-1,604,500	-1,879,000	-1,939,000	-2,799,000
Net Income Margin	-327.1%	-0.02	0.01	0.04	-0.13	-0.13	-0.15	-0.15	-0.14	-0.13	-0.09	-0.06	-0.05	-	-	-	-	-	-	-	-	-
Free Cashflow	-414.3%	-6,573,000	-1,278,000	-4,057,000	-2,935,000	-2,701,000	-2,731,000	-2,575,000	-311,000	-1,488,000	-203,000	-1,336,000	1,712,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	1.4%	94.00	93.00	92.00	65.00	63.00	60.00	56.00	53.00	53.00	55.00	56.00	60.00	59.00	41.00	42.00	42.00	43.00	43.00	43.00	44.00	47.00
Current Assets	2.6%	67.00	65.00	64.00	40.00	37.00	49.00	45.00	42.00	43.00	44.00	46.00	49.00	48.00	31.00	32.00	31.00	32.00	32.00	32.00	32.00	34.00
Cash Equivalents	-20.4%	5.00	6.00	9.00	4.00	5.00	20.00	17.00	16.00	17.00	18.00	18.00	20.00	19.00	2.00	3.00	3.00	3.00	5.00	6.00	7.00	7.00
Inventory	5.0%	39.00	37.00	34.00	20.00	19.00	17.00	17.00	16.00	17.00	18.00	20.00	21.00	22.00	21.00	21.00	20.00	18.00	16.00	16.00	16.00	17.00
Net PPE	2.0%	9.00	9.00	9.00	7.00	7.00	6.00	6.00	6.00	5.00	5.00	5.00	5.00	5.00	4.00	4.00	4.00	4.00	5.00	5.00	6.00	6.00
Goodwill	0%	7.00	7.00	7.00	7.00	8.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
Liabilities	12.1%	46.00	41.00	37.00	34.00	31.00	26.00	23.00	25.00	24.00	24.00	23.00	26.00	25.00	27.00	90.00	89.00	89.00	87.00	86.00	86.00	86.00
Current Liabilities	23.7%	28.00	23.00	22.00	17.00	17.00	15.00	11.00	12.00	11.00	11.00	10.00	13.00	24.00	26.00	9.00	9.00	10.00	9.00	9.00	10.00	11.00
Long Term Debt	-2.0%	17.00	17.00	14.00	16.00	12.00	10.00	11.00	12.00	12.00	12.00	12.00	12.00	-	-	80.00	78.00	77.00	76.00	75.00	74.00	73.00
LT Debt, Current	-	-	-	3.00	1.00	5.00	2.00	1.00	-	-	-	-	-	16.00	17.00	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	17.00	14.00	16.00	12.00	10.00	11.00	12.00	12.00	12.00	12.00	12.00	-	-	80.00	78.00	77.00	76.00	75.00	74.00	73.00
Shareholder's Equity	-7.1%	48.00	51.00	55.00	31.00	33.00	34.00	33.00	28.00	29.00	31.00	33.00	34.00	33.00	15.00	48.00	-	-	-	-	-	-
Retained Earnings	-1.8%	-247	-243	-238	-247	-245	-243	-241	-239	-237	-235	-232	-231	-230	-230	-229	-228	-225	-223	-221	-219	-217
Additional Paid-In Capital	0.3%	295	294	294	279	278	278	274	267	267	266	266	265	264	245	182	181	179	179	179	179	179
Shares Outstanding	0.0%	130	130	130	109	109	109	89.00	87.00	87.00	87.00	87.00	87.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	26.00	-	-	-	7.00	-	-	-	22.00	-	-	-	4.00	-	-	-	12.00	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-533.9%	-5,800	-915	-3,834	-2,521	-2,245	-2,288	-2,064	15.00	-1,004	423	-926	2,249	-1,307	916	-71.00	213	-1,789	-71.00	-1,296	464	490
Share Based Compensation	-3.0%	910	938	745	439	617	639	641	571	613	708	580	465	456	358	237	220	269	259	95.00	39.00	122
Cashflow From Investing	70.9%	-674	-2,313	-4,656	-394	-17,421	-422	-492	-254	-391	-595	-341	-471	-483	-570	-167	-392	-175	-382	-114	38.00	-86.00
Cashflow From Financing	1493.5%	5,179	325	12,844	1,953	4,569	5,614	3,312	115	-21.00	-55.00	-646	106	18,092	-746	-40.00	-41.00	-34.00	-59.00	-159	-281	-104

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

XTNT Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 27,873	$ 17,943
Cost of sales	10,571	7,407
Gross Profit	17,302	10,536
Operating Expenses
General and administrative	7,785	4,884
Sales and marketing	12,460	7,054
Research and development	527	174
Total Operating Expenses	20,772	12,112
Loss from Operations	(3,470)	(1,576)
Other Expense
Interest expense	(835)	(575)
Interest income		86
Unrealized foreign currency translation loss	(39)
Other income	12
Total Other Expense	(862)	(489)
Net Loss from Operations Before Provision for Income Taxes	(4,332)	(2,065)
Provision for Income Taxes Current and Deferred	(68)	(13)
Net Loss	$ (4,400)	$ (2,078)
Net Loss Per Share:
Basic	$ (0.03)	$ (0.02)
Dilutive	$ (0.03)	$ (0.02)
Shares used in the computation:
Basic	130,201,251	108,893,588
Dilutive	130,201,251	108,893,588

XTNT Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 4,547	$ 5,715
Restricted cash	77	208
Trade accounts receivable, net of allowance for credit losses and doubtful accounts of $954 and $920, respectively	21,484	20,731
Inventories	38,724	36,885
Prepaid and other current assets	1,709	1,330
Total current assets	66,541	64,869
Property and equipment, net	8,867	8,692
Right-of-use asset, net	1,437	1,523
Goodwill	7,302	7,302
Intangible assets, net	9,652	10,085
Other assets	132	141
Total Assets	93,931	92,612
Current Liabilities:
Accounts payable	7,378	7,054
Accrued liabilities	9,875	10,419
Current portion of lease liability	853	830
Current portion of finance lease obligations	66	65
Line of credit	10,270	4,622
Total current liabilities	28,442	22,990
Long-term Liabilities:
Lease liability, less current portion	644	759
Finance lease obligation, less current portion	99	116
Long-term debt, plus premium and less issuance costs	16,826	17,167
Other liabilities	240	231
Total Liabilities	46,251	41,263
Commitments and Contingencies (note 14)
Stockholders’ Equity:
Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.000001 par value; 300,000,000 shares authorized; 130,216,541 shares issued and outstanding as of March 31, 2024 and 130,180,031 shares issued and outstanding as of December 31, 2023
Additional paid-in capital	295,223	294,330
Accumulated other comprehensive (loss) income	(133)	29
Accumulated deficit	(247,410)	(243,010)
Total Stockholders’ Equity	47,680	51,349
Total Liabilities & Stockholders’ Equity	$ 93,931	$ 92,612

About Xtant Medical Holdings Inc

Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor, which contains various proteins and peptides that support bone formation and remodeling; OsteoWrap; and OsteoVive Plus, a growth factor enriched cellular bone matrix. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, Xpress minimally invasive pedicle screw, and Fortex Pedicle screw systems. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.

CEO	Mr. Sean E. Browne
WEBSITE	xtantmedical.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	134

Xtant Medical Holdings Inc Frequently Asked Questions

What is the ticker symbol for Xtant Medical Holdings Inc? What does XTNT stand for in stocks?

XTNT is the stock ticker symbol of Xtant Medical Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Xtant Medical Holdings Inc (XTNT)?

As of Fri May 17 2024, market cap of Xtant Medical Holdings Inc is 95.06 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of XTNT stock?

You can check XTNT's fair value in chart for subscribers.

What is the fair value of XTNT stock?

You can check XTNT's fair value in chart for subscribers. The fair value of Xtant Medical Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Xtant Medical Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for XTNT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Xtant Medical Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether XTNT is over valued or under valued. Whether Xtant Medical Holdings Inc is cheap or expensive depends on the assumptions which impact Xtant Medical Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XTNT.

What is Xtant Medical Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, XTNT's PE ratio (Price to Earnings) is -57.19 and Price to Sales (PS) ratio is 0.94. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XTNT PE ratio will change depending on the future growth rate expectations of investors.